263 related articles for article (PubMed ID: 26846787)
41. Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy.
Kerns E; Rozansky D; Troxell ML
Pediatr Nephrol; 2013 Nov; 28(11):2227-31. PubMed ID: 23892798
[TBL] [Abstract][Full Text] [Related]
42. Differences between membranoproliferative glomerulonephritis types I and III in long-term response to an alternate-day prednisone regimen.
Braun MC; West CD; Strife CF
Am J Kidney Dis; 1999 Dec; 34(6):1022-32. PubMed ID: 10585311
[TBL] [Abstract][Full Text] [Related]
43. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation.
Zand L; Lorenz EC; Cosio FG; Fervenza FC; Nasr SH; Gandhi MJ; Smith RJ; Sethi S
J Am Soc Nephrol; 2014 May; 25(5):1110-7. PubMed ID: 24357668
[TBL] [Abstract][Full Text] [Related]
44. Discordant renal histopathologic findings and complement profiles in membranoproliferative glomerulonephritis type III.
Meyers KE; Strife CF; Witzleben C; Kaplan BS
Am J Kidney Dis; 1996 Dec; 28(6):804-10. PubMed ID: 8957031
[TBL] [Abstract][Full Text] [Related]
45. Focal segmental membranoproliferative glomerulonephritis in children.
Iitaka K; Nakamura S; Moriya S; Motoyama O; Sakai T
Pediatr Nephrol; 2003 Oct; 18(10):1000-4. PubMed ID: 12883968
[TBL] [Abstract][Full Text] [Related]
46. Myeloid-related protein 8 expression on macrophages is a useful prognostic marker for renal dysfunction in children with MPGN type 1.
Kawasaki Y; Hosoya M; Takahashi A; Isome M; Tanji M; Suzuki H
Am J Kidney Dis; 2005 Mar; 45(3):510-8. PubMed ID: 15754273
[TBL] [Abstract][Full Text] [Related]
47. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.
Licht C; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):271-8. PubMed ID: 19190809
[TBL] [Abstract][Full Text] [Related]
48. The incidence of possible causes of membranoproliferative glomerulonephritis: a single-center experience.
Pavinic J; Miglinas M
Hippokratia; 2015; 19(4):314-8. PubMed ID: 27688695
[TBL] [Abstract][Full Text] [Related]
49. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis.
Gupta N; Wakefield DN; Clapp WL; Garin EH
Nefrologia; 2017; 37(1):78-86. PubMed ID: 27595516
[TBL] [Abstract][Full Text] [Related]
50. [Prominent subepithelial deposits detected on 2nd renal biopsy in a boy with membranoproliferative glomerulonephritis type I: a case report].
Motoyama O; Ohshima M; Kawamura S; Iitaka K
Nihon Jinzo Gakkai Shi; 1995 Apr; 37(4):247-52. PubMed ID: 7602812
[TBL] [Abstract][Full Text] [Related]
51. A Case of Switch from C3 Glomerulonephritis to Proliferative Glomerulonephritis with Monoclonal IgG Deposits.
Zhang F; Gao E; Liang S; Yang N; Wang J
Ann Clin Lab Sci; 2018 Jul; 48(4):528-533. PubMed ID: 30143498
[TBL] [Abstract][Full Text] [Related]
52. De novo C3 glomerulonephritis in a renal allograft.
Nahm JH; Song SH; Kim YS; Cheong HI; Lim BJ; Kim BS; Jeong HJ
Ultrastruct Pathol; 2016; 40(2):112-5. PubMed ID: 26986539
[TBL] [Abstract][Full Text] [Related]
53. Idiopathic membranoproliferative glomerulonephritis in Japanese children.
Iitaka K; Ishidate T; Hojo M; Kuwao S; Kasai N; Sakai T
Pediatr Nephrol; 1995 Jun; 9(3):272-7. PubMed ID: 7632509
[TBL] [Abstract][Full Text] [Related]
54. [C3 production by peripheral blood monocytes in patients with membranoproliferative glomerulonephritis and poststreptococcal glomerulonephritis].
Yan K
Nihon Jinzo Gakkai Shi; 1993 Feb; 35(2):151-60. PubMed ID: 8315878
[TBL] [Abstract][Full Text] [Related]
55. Mononuclear cell subsets in IgM mesangial proliferative glomerulonephritis. A comparative study with minimal change nephrotic syndrome and immunonegative mesangial proliferative glomerulonephritis.
Garcia del Moral R; Gomez-Morales M; Cortes V; Aguayo ML; Gigosos RL; Lardelli P; Navas A; Aneiros J; Aguilar D
Nephron; 1993; 65(2):215-21. PubMed ID: 8247183
[TBL] [Abstract][Full Text] [Related]
56. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.
Bomback AS; Appel GB
Nat Rev Nephrol; 2012 Nov; 8(11):634-42. PubMed ID: 23026947
[TBL] [Abstract][Full Text] [Related]
57. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion.
Sethi S; Nester CM; Smith RJ
Kidney Int; 2012 Mar; 81(5):434-41. PubMed ID: 22157657
[TBL] [Abstract][Full Text] [Related]
58. Serum terminal complement component levels in hypocomplementemic glomerulonephritides.
Clardy CW; Forristal J; Strife CF; West CD
Clin Immunol Immunopathol; 1989 Mar; 50(3):307-20. PubMed ID: 2917423
[TBL] [Abstract][Full Text] [Related]
59. Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment.
Noris M; Daina E; Remuzzi G
Nephrol Dial Transplant; 2023 Feb; 38(2):283-290. PubMed ID: 34596686
[TBL] [Abstract][Full Text] [Related]
60. Long-term follow-up of atypical membranoproliferative glomerulonephritis: are steroids indicated?
Fujita T; Nozu K; Iijima K; Kamioka I; Yoshiya K; Tanaka R; Hamahira K; Nakanishi K; Yoshikawa N; Matsuo M
Pediatr Nephrol; 2006 Feb; 21(2):194-200. PubMed ID: 16247645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
